The educational design of this activity addresses the needs of nephrologists, cardiologists, hematologists, endocrinologists, internal medicine physicians, and other clinicians involved in the management of patients with anemia associated with chronic kidney disease (CKD).
In this activity, Dr. Bruce Spinowitz and Dr. Ajay Singh discuss the clinical trial research relating to the use of HIF-PH inhibitors to treat anemia in patients with CKD. They examine the benefits and the cardiovascular concerns surrounding newer agents, such as roxadustat, vadadustat, and daprodustat. As nephrologists, they discuss the unmet need these agents may fill and describe how these oral medications can address the health-related quality of life and health disparities they see among their patient populations.
After completing this activity, the participant should be better able to:
Discuss the mechanisms of action and clinical trial data for emerging treatment options, such as HIF-PH inhibitors, in the treatment of anemia associated with CKD
Tailor management regimens for anemia associated with CKD to reflect disease presentation, treatment responses, efficacy and safety of available therapies, and efforts to address disparities in healthcare and patient outcomes
Ajay K. Singh, MBBS, FRCP, MBA
Senior Associate Dean for Postgraduate Medical Education
Director, Master in Medical Sciences in Clinical Investigation (MMSCI) Program
Harvard Medical School
Physician, Renal Division
Brigham and Women’s Hospital/ Dana Farber Cancer Institute
Bruce S. Spinowitz, MD
Associate Director of Nephrology
Vice Chairman of the Department of Medicine
New York Presbyterian Queens
Professor of Clinical Medicine
Weill Cornell Medical College
New York, New York
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Continuing Education
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global nd Integritas Communications. Global is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.25 contact hour (which includes 0.1 hour(s) of pharmacology).
Global Contact Information
For information about the approval of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must pass the posttest with 100% and complete the program evaluation.
Fee Information& Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosures of Conflicts of Interest
Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Ajay K. Singh, MBBS, FRCP, MBA: Consulting Fee: GlaxoSmithKline plc, Bayer AG, Zydus Lifesciences Limited, Nephrology Times; Honoraria: University of North Carolina
Bruce S. Spinowitz, MD: Consulting Fee: Akebia Therapeutics Inc., AstraZeneca Pharmaceuticals LP, GlaxoSmithKline plc; Contracted Research: Akebia Therapeutics Inc., AstraZeneca Pharmaceuticals LP, GlaxoSmithKline plc, Omeros Corporation; Speakers’ Bureau: AstraZeneca Pharmaceuticals LP, Bayer AG, Fresenius Medical Care AG & Co.
The following planners and managers have no relevant financial relationships with ineligible companies:
Kristin Delisi, NP, Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Lauren Sinclair, Stacey JP Ullman, MHS, Celeste Collazo, MD, Jim Kappler, PhD
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications Group do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.